Uterine (Endometrial) Cancer

    Actionable Target Abnormality Prevalence (%) (1) Clinical Experience with Targeted Agent
    PTEN Mutation 43 (endometrioid)
    0–11 (non-endometrioid)
    MKC-1 (AKT/tubulin inhibitor):
    • Phase 2: RR 0%, SD 44% (2)
    Temsirolimus (mTOR inhibitor):
    • Phase 2: RR 4%–14%, SD 28%–69% (3)
    • Phase 2 (with megace/tamoxifen vs. temsirolimus alone): RR 22% vs. 14% in the combination arm (4)
    Everolimus (mTOR inhibitor):
    • Phase 2: SD 43% (5)
    • Phase 2, with letrozole: RR 21%, SD 21% (6)
    • Phase 2 (with letrozole and metformin): RR 29%, SD 38% (7)
    Ridaforolimus (mTOR inhibitor):
    Other topics in Targets by Organ Site